ALR Technologies and Aspire Cerebro Advertising have inked a marketing deal in India for the ALRT diabetes management system.
Aspira Cerebro Advertising plans to create a comprehensive marketing plan for the ALRT Diabetes Solution system, with the intent of bringing the technology to India’s estimated 100 million diabetes patients.
“Our model enables pharmaceutical companies to provide the ALRT Diabetes Solution to health clinics and simplify delivery of best-practice diabetes care. This will increase the efficiency of the clinics, and improve health outcomes for patients suffering from diabetes in India,” ALR chairman & CEO Sidney Chan said in prepared remarks.
“We are excited to launch ALRT in India. They have technology to improve patient outcomes,” Amit Bhagchandani, founder & mentor of Aspire Cerebro, added. “To bring the best of healthcare solutions to India, ALRT Technologies empowers our mission of inspiring healthier lives.”
“ALRT Diabetes Solution will make a significant difference in lives of diabetes patients. We immediately recognized the value it could bring to patients, HCPs and our clients,” Sanjeev Chopra, CEO of Aspire Cerebro said. “We are looking forward to introducing ALRT to Indian markets.”
ALR’s ALRT system combines data from blood glucose meters with an FDA-approved insulin dosing adjustment feature that suggests insulin dosing changes. The company’s system also includes performance tracking features to monitor treatment success in between visits to the doctor.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.